Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

The essential job of precision medicine is to match the right drugs to the right patients. In
cancer, precision medicine has been nearly synonymous with genomics. However, sobering …

Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-
adapted based on clinical features, leukemia genomics and minimal residual disease …

The last decade has witnessed great advances in our understanding of the genetic and
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

We investigated and modeled the mesenchymal stromal cell (MSC) niche in adult acute
lymphoblastic leukemia (ALL). We used gene expression profiling, cytokine/chemokine …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy and
new therapeutics are much needed. Profiling patient leukemia drug sensitivities ex vivo, we …

In-depth modeling of the complex interplay among multiple omics data measured from
cancer cell lines or patient tumors is providing new opportunities toward identification of …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy
characterized by aberrant proliferation of immature thymocytes. Despite an overall survival …

Acute lymphoblastic leukemia (ALL) is the most successful paradigm of how risk-adapted
therapy and detailed understanding of the genetic alterations driving leukemogenesis and …